Sun Pharmaceutical Industries Limited announced that they have reached an agreement with Celgene Corporation to resolve the patent litigation regarding submission of an Abbreviated New Drug Application for a generic version of Revlimid® (lenalidomide capsules) in the US. Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a license to Celgene's patents required to manufacture and sell (subject to USFDA approval) certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022. In addition, the license will also allow Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning January 31, 2026.